PMID- 35143119
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20220531
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 130
IP  - 5
DP  - 2022 May
TI  - Analysis of early pleural fluid samples in patients with mesothelioma: A case 
      series exploration of morphology, BAP1, and CDKN2A status with implications for 
      the concept of mesothelioma in situ in cytology.
PG  - 352-362
LID - 10.1002/cncy.22548 [doi]
AB  - BACKGROUND: The concept of mesothelioma in situ has been revisited and is a new 
      World Health Organization diagnostic entity. The definition centers on ancillary 
      techniques used in pleural mesothelioma (PM) assessment. At the authors' 
      institution, most PM diagnoses are made on cytologic specimens. Effusion samples 
      obtained before definitive PM diagnosis were interrogated using BRCA1-associated 
      protein 1 gene (BAP1), cyclin-dependent kinase inhibitor 2A gene (CDKN2A) and 
      cytologic evaluation to assess whether early or possible in situ disease could be 
      characterized. METHODS: All cases of PM diagnosed between January 2008 and 
      December 2019 were identified at a tertiary referral center. Patients who had a 
      pleural fluid sample collected 24 months before the diagnosis were selected, 
      numbering 8 in total. The cytomorphology of each sample was reviewed; and, 
      retrospectively, BAP1 immunohistochemistry (IHC) and CDKN2A fluorescence in situ 
      hybridization (FISH) were performed on initial and diagnostic samples. RESULTS: 
      The initial samples were deemed benign in 5 cases and atypical mesothelial 
      proliferations in 3 cases. A spectrum of apparently normal to atypical 
      cytomorphologic changes was identified. BAP1 loss was present in 6 of 8 initial 
      cases, whereas CDKN2A homozygous deletion was identified in 1 of 7 initial cases. 
      Either abnormality was identified in 7 of 8 initial samples. CONCLUSIONS: 
      Detectable abnormalities of BAP1 IHC and CDKN2A FISH were present in pleural 
      fluid specimens before the development of cytomorphologic features diagnostic of 
      PM. This is the largest series to date describing cytology samples early in the 
      course of PM development, thereby highlighting a possible cytological equivalent 
      for mesothelioma in situ.
CI  - (c) 2022 American Cancer Society.
FAU - Louw, Amber
AU  - Louw A
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
AD  - School of Medical and Health Sciences, Edith Cowan University, Perth, Western 
      Australia, Australia.
AD  - Institute for Respiratory Health, Nedlands, Western Australia, Australia.
AD  - National Center for Asbestos Related Diseases, University of Western Australia, 
      Nedlands, Western Australia, Australia.
FAU - van Vliet, Chris
AU  - van Vliet C
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
FAU - Peverall, Joanne
AU  - Peverall J
AD  - Department of Diagnostic Genomics, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
FAU - Colkers, Shane
AU  - Colkers S
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
FAU - Acott, Nathan
AU  - Acott N
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
FAU - Creaney, Jenette
AU  - Creaney J
AD  - Institute for Respiratory Health, Nedlands, Western Australia, Australia.
AD  - National Center for Asbestos Related Diseases, University of Western Australia, 
      Nedlands, Western Australia, Australia.
AD  - Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, 
      Western Australia, Australia.
FAU - Lee, Y C Gary
AU  - Lee YCG
AD  - Institute for Respiratory Health, Nedlands, Western Australia, Australia.
AD  - Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, 
      Western Australia, Australia.
AD  - School of Medicine, University of Western Australia, Nedlands, Western Australia, 
      Australia.
FAU - Chai, Siaw Ming
AU  - Chai SM
AUID- ORCID: 0000-0002-7941-5561
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth 
      II Medical Center, Nedlands, Western Australia, Australia.
LA  - eng
PT  - Journal Article
DEP - 20220210
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (BAP1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - Homozygote
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/diagnosis/genetics
MH  - *Mesothelioma/diagnosis/genetics
MH  - *Mesothelioma, Malignant
MH  - *Pleural Neoplasms/diagnosis/genetics
MH  - Retrospective Studies
MH  - Sequence Deletion
MH  - Tumor Suppressor Proteins/genetics
MH  - Ubiquitin Thiolesterase/genetics
OTO - NOTNLM
OT  - BRCA1-associated protein 1 (BAP1)
OT  - cyclin-dependent kinase inhibitor 2A gene (CDKN2A)
OT  - cytology
OT  - mesothelioma
OT  - mesothelioma in situ
EDAT- 2022/02/11 06:00
MHDA- 2022/05/10 06:00
CRDT- 2022/02/10 12:17
PHST- 2021/11/11 00:00 [revised]
PHST- 2021/09/10 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
PHST- 2022/02/10 12:17 [entrez]
AID - 10.1002/cncy.22548 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2022 May;130(5):352-362. doi: 10.1002/cncy.22548. Epub 2022 
      Feb 10.